SCHEMBL12744415

SCHEMBL12744415

CCN(c1ccc(Cl)cc1Cl)C1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.43
TP53 P04637 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
LMNA P02545 3/20 0.41
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 3/20 0.39
FSCN1 Q16658 1/20 0.38
SIGMAR1 Q99720 3/20 0.37
TMEM97 Q5BJF2 1/20 0.37
EBP Q15125 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
POLB P06746 1/20 0.36
SLC6A4 P31645 2/20 0.36
SLC6A3 Q01959 2/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP3A4 P08684 1/20 0.36
SLC6A2 P23975 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6811989 0.85 HSD11B1 (0.38) TSHRTP53LMNAKDM4EALDH1A1
SCHEMBL11127078 0.80 TSHR (0.52) TSHRTP53NPC1RAB9AKDM4E
SCHEMBL6810968 0.79 ALDH1A1 (0.50) TP53ALDH1A1MEN1KMT2APOLB
SCHEMBL9909358 0.79 NPC1 (0.48) TSHRTP53NPC1RAB9AKDM4E
Hydrochloric Acid SCHEMBL1432259 0.76 RAB9A (0.41) TSHRTP53NPC1RAB9ALMNA
SCHEMBL9908232 0.75 NPC1 (0.42) TSHRTP53NPC1RAB9ALMNA
SCHEMBL11694032 0.75 TP53 (0.48) TSHRTP53NPC1RAB9ALMNA
SCHEMBL12715258 0.75 NPC1 (0.45) TSHRNPC1RAB9ALMNAKDM4E
SCHEMBL18830512 0.74 EZH2 (0.44) TP53
SCHEMBL7340915 0.73 NOS3 (0.36) TP53NPC1RAB9ALMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7923465-B2 CB2 agonists; pain, neurodegenative disorders, eating disorders, weight loss or control, obesity, dyslipidemia, drug abuse, vision defect, neurodegenerative diseases; 5-(2,4-difluorophenyl)-4,5-diazatricyclo[5.2.1.0.sup.2,6.]deca-2-(6),3-dien-3-yl-phenylmethanone; antiinflammatory agent, antidepressant GLENMARK PHARMACEUTICALS S.A. (CH) 2011-04-12 US disclosed
US-20080234259-A1 Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation GLENMARK PHARMACEUTICALS S.A. (CH) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234259-A1 Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation CNR2, CNR1, OPRL1 TSHR 1819/4885TP53 4825/4885NPC1 581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.